Motomu Hashimoto
Motomu Hashimoto is an expert in Rheumatology at Osaka Metropolitan University Hospital (Japan). As of October 2026, ScienceLeadR ranks Motomu Hashimoto in the top 1% of experts worldwide for Autoimmune Diseases, Arthritis and Epidemiologic Studies. Motomu Hashimoto has authored 330 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 1 of them ongoing. SLR score: 1,107 (community average: 125). How the SLR is computed.
LeadR Profile
Rheumatology
Subspecialties: Immunology - Internal Medicine - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Trained under Prof. Shimon Sakaguchi, the 2025 Nobel Laureate recognized for the discovery of regulatory T cells, Prof. Motomu Hashimoto has advanced pioneering research bridging basic and clinical immunology. His work using a monogenic autoimmune mouse model has elucidated mechanisms through which genetic and environmental factors determine disease phenotypes—including rheumatoid arthritis, systemic lupus erythematosus, and spondyloarthritis. In clinical research, Prof. Hashimoto established the ANSWER cohort, Japan’s largest rheumatoid arthritis registry, generating real-world evidence that informs the optimal use of molecular targeted therapies. His major contributions integrating bench and bedside research were honored with the 2025 Japan College of Rheumatology Scientific Award.
Key Research Achievements
Basic research
1. Yoshida T, Hashimoto M. et al. Arthritis Res Ther. 2025 ;27(1):143
2. Katsushima M, Hashimoto M. et al. Rheumatology (Oxford). 2025 ;64(5):3104-3115
3. Shirakashi M, Hashimoto M. et al. Arthritis Rheumatol. 2022 ;74(4):641-653.
4. Tabuchi Y, Hashimoto M. et al. Arthritis Res Ther. 2022 ;24(1):176.
5. Matsuo T, Hashimoto M. et al. J Immunol. 2019;202(11):3161-3172.
6. Hirota K, Hashimoto M, et al. Immunity. 2018: S1074-7613(18)30146-8.
7. Ito Y, Hashimoto M, et al. Science. 2014;346(6207):363-8.
8. Hashimoto M, et al. J Exp Med. 2010;207(6):1135-43.
Clinical Research
1. Torii M, Hashimoto M. et al. Arthritis Res Ther. 2026;28(1):66.
2. Smolen JS, Hashimoto M, Taylor PC, et al. RMD Open. 2026 ;12(1):e006094
3. Fujisawa Y, Hashimoto M. et al. Rheumatology (Oxford). 2026 ;65(2):keaf602.
4. Watanabe R, Hashimoto M. et al. Rheumatology (Oxford). 2024 ;63(9):2418-2426.
5. Nakayama Y, Hashimoto M. et al. Rheumatology (Oxford). 2024; 63(2):349-357.
6. Iwasaki T, Hashimoto M. et al. Front Immunol. 2022 6;13:901437.
7. Nakayama Y, Hashimoto M. et al. Rheumatol Int. 2022 ;42(7):1227-1234.
8. Hashimoto M, et al. Arthritis Res Ther. 2018;20(1):165. .
9. Hashimoto M, et al. PLoS One. 2015;10:e0122121.
Organizations
Career arc: 2000 - 2026
Number : 330
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Comparative effectiveness and safety of five Janus kinase inhibitors in real-world clinical practice: the multicentre ANSWER cohort. PMID 42949113 — safety, rheumatic diseases, drug-related side effects and adverse reactions, janus kinases, therapeutics, janus kinase inhibitors | Rheumatology (Oxford) | 2026 | 0 |
| Burden of herpes zoster and recombinant zoster vaccine willingness in systemic lupus erythematosus: A single-center cohort study. PMID 42803531 — vaccines, azathioprine, cohort studies, lupus erythematosus, systemic, herpes zoster, diagnosis, herpes zoster vaccine, immunosuppression therapy | Lupus | 2026 | 0 |
| Reasons-stratified treatment retention after JAK inhibitor discontinuation in rheumatoid arthritis: the ANSWER cohort study. PMID 42900496 — pharmaceutical preparations, arthritis, cohort studies, rheumatic diseases, arthritis, rheumatoid, therapeutics, janus kinase inhibitors, retention, psychology | Rheumatology (Oxford) | 2026 | 0 |
| CD40-CD40L interactions in systemic autoimmune diseases. PMID 42885554 — rheumatic diseases, lupus erythematosus, systemic, cd40 ligand, autoimmune diseases, arthritis, rheumatoid, blood platelets, tissues | Rheumatology (Oxford) | 2026 | 0 |
| Comment on: early rheumatoid factor decline predicts subsequent clinical remission in rheumatoid arthritis: the ANSWER cohort: Reply. PMID 42886529 — arthritis, rheumatic diseases, arthritis, rheumatoid, rheumatoid factor | Rheumatology (Oxford) | 2026 | 0 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS 986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus NCT05620407 — safety, connective tissue, connective tissue diseases, lupus erythematosus, systemic, immune system diseases, immune system, autoimmune diseases, tissues | Phase 3 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map